Roth Capital Predicts Reduced Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Roth Capital cut their Q4 2025 EPS estimates for Globus Medical in a research report issued on Wednesday, November 6th. Roth Capital analyst J. Wittes now anticipates that the medical device company will earn $0.91 per share for the quarter, down from their previous estimate of $0.92. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share.

Several other brokerages have also weighed in on GMED. Roth Mkm reissued a “buy” rating and issued a $100.00 price objective on shares of Globus Medical in a report on Wednesday. Piper Sandler upped their price target on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday. BTIG Research lifted their price objective on shares of Globus Medical from $77.00 to $78.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Royal Bank of Canada increased their target price on Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Canaccord Genuity Group boosted their price objective on Globus Medical from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.09.

Globus Medical Trading Down 0.9 %

Shares of NYSE GMED opened at $81.97 on Thursday. The stock has a fifty day simple moving average of $71.92 and a two-hundred day simple moving average of $68.16. Globus Medical has a 1-year low of $43.38 and a 1-year high of $84.87. The firm has a market cap of $11.10 billion, a price-to-earnings ratio of 273.23, a price-to-earnings-growth ratio of 2.06 and a beta of 1.17.

Globus Medical (NYSE:GMED) last released its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. Globus Medical had a net margin of 1.82% and a return on equity of 8.70%. The firm had revenue of $625.71 million during the quarter, compared to the consensus estimate of $604.69 million. During the same period in the prior year, the firm earned $0.57 EPS. The company’s revenue was up 63.1% compared to the same quarter last year.

Institutional Investors Weigh In On Globus Medical

A number of large investors have recently added to or reduced their stakes in GMED. Pathstone Holdings LLC lifted its holdings in Globus Medical by 2.6% in the 3rd quarter. Pathstone Holdings LLC now owns 41,007 shares of the medical device company’s stock worth $2,934,000 after buying an additional 1,055 shares during the period. Quest Partners LLC purchased a new position in Globus Medical during the 3rd quarter valued at $523,000. Sheaff Brock Investment Advisors LLC raised its holdings in Globus Medical by 0.8% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 39,024 shares of the medical device company’s stock worth $2,792,000 after purchasing an additional 321 shares in the last quarter. KBC Group NV lifted its position in shares of Globus Medical by 0.5% in the 3rd quarter. KBC Group NV now owns 45,505 shares of the medical device company’s stock worth $3,255,000 after purchasing an additional 237 shares during the period. Finally, Geneva Capital Management LLC boosted its stake in shares of Globus Medical by 1.1% during the 3rd quarter. Geneva Capital Management LLC now owns 1,598,130 shares of the medical device company’s stock valued at $114,330,000 after purchasing an additional 18,117 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 30,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the completion of the sale, the director now directly owns 536,275 shares in the company, valued at $40,242,076. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Globus Medical news, Director David D. Davidar sold 30,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the transaction, the director now directly owns 536,275 shares of the company’s stock, valued at approximately $40,242,076. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ann D. Rhoads sold 15,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the sale, the director now owns 42,884 shares of the company’s stock, valued at approximately $3,017,318.24. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.54% of the stock is owned by company insiders.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.